Literature DB >> 21546321

Laparoscopic sleeve gastrectomy and laparoscopic gastric bypass are equally effective for reduction of cardiovascular risk in severely obese patients at one year of follow-up.

David Benaiges1, Albert Goday, Jose M Ramon, Elisa Hernandez, Manuel Pera, Juan F Cano.   

Abstract

BACKGROUND: Very few studies have compared laparoscopic Roux-en-Y gastric bypass (LRYGB) and laparoscopic sleeve gastrectomy (LSG) outcomes or analyzed improvement in cardiovascular risk (CVR) after bariatric surgery. None of the studies considered the Mediterranean population. Our primary objective was to compare the 10-year estimated CVR reduction achieved by LRYGB and LSG in Spanish subjects with severe obesity. The secondary objectives were to compare the techniques in terms of weight loss and co-morbidity improvement. The study was performed at a university hospital in Barcelona, Spain.
METHODS: A 12-month prospective cohort study of 140 consecutive patients (95 LRYGB and 45 LSG) compared the 2 surgical intervention groups to study the percentage of excess weight loss, resolution and improvement/resolution of co-morbidities, and effect on CVR using both the Framingham risk score (FRS) and the Registre Gironí del Cor (REGICOR) model.
RESULTS: At 12 months, the overall CVR decreased from 6.6% to 3.4% using the FRS and from 3.7% to 1.9% using the REGICOR score. Neither model found a difference between the 2 surgical intervention groups in decreased postoperative CVR risk, with a FRS of 3.4% ± 2.2% for LRYGB versus 3.3% ± 2.1% for LSG (P = .872) and a REGICOR score of 1.9% ± 1.5% versus 1.8% ± 1.6%, respectively (P = .813). No differences were observed in the percentage of excess weight loss or the resolution of type 2 diabetes mellitus and hypertension. The hypercholesterolemia improvement/resolution rate was lower in the LSG group than in the LRYGB group.
CONCLUSION: Bariatric surgery reduces the estimated CVR by one half at 1 year after surgery. Except for the less-improved cholesterol metabolism, LSG, a restrictive technique, proved to be equally as effective at 1 year of follow-up as LRYGB. Crown
Copyright © 2011. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21546321     DOI: 10.1016/j.soard.2011.03.002

Source DB:  PubMed          Journal:  Surg Obes Relat Dis        ISSN: 1550-7289            Impact factor:   4.734


  49 in total

1.  Effect of Roux-en-Y gastric bypass vs sleeve gastrectomy on glucose and gut hormones: a prospective randomised trial.

Authors:  José Manuel Ramón; Silvia Salvans; Xenia Crous; Sonia Puig; Albert Goday; David Benaiges; Lourdes Trillo; Manuel Pera; Luis Grande
Journal:  J Gastrointest Surg       Date:  2012-03-09       Impact factor: 3.452

Review 2.  Bariatric surgery: effects on the metabolic complications of obesity.

Authors:  Peter M Clifton
Journal:  Curr Atheroscler Rep       Date:  2012-04       Impact factor: 5.113

3.  Lack of adherence to follow-up visits after bariatric surgery: reasons and outcome.

Authors:  Pablo Vidal; José Manuel Ramón; Alberto Goday; Alejandra Parri; Xènia Crous; Lourdes Trillo; Manuel Pera; Luis Grande
Journal:  Obes Surg       Date:  2014-02       Impact factor: 4.129

4.  Cardiovascular risk in obese diabetic patients is significantly reduced one year after gastric bypass compared to one year of diabetes support and education.

Authors:  Alessandro Mor; Philip Omotosho; Alfonso Torquati
Journal:  Surg Endosc       Date:  2014-05-23       Impact factor: 4.584

5.  RYGB Is More Effective than VSG at Protecting Mice from Prolonged High-Fat Diet Exposure: An Occasion to Roll Up Our Sleeves?

Authors:  Matthew Stevenson; Ankita Srivastava; Jenny Lee; Christopher Hall; Thomas Palaia; Raymond Lau; Collin Brathwaite; Louis Ragolia
Journal:  Obes Surg       Date:  2021-04-15       Impact factor: 4.129

6.  Predictive Value of Gut Peptides in T2D Remission: Randomized Controlled Trial Comparing Metabolic Gastric Bypass, Sleeve Gastrectomy and Greater Curvature Plication.

Authors:  Anna Casajoana; Jordi Pujol; Amador Garcia; Jordi Elvira; Nuria Virgili; Francisco Javier de Oca; Xavier Duran; Sonia Fernández-Veledo; Joan Vendrell; Nuria Vilarrasa
Journal:  Obes Surg       Date:  2017-09       Impact factor: 4.129

7.  Laparoscopic sleeve gastrectomy versus laparoscopic Roux-en-Y gastric bypass for morbid obesity and related comorbidities: a meta-analysis of 21 studies.

Authors:  Yong Zhang; Ju Wang; Wang Ju; Xiangyu Sun; Zhangou Cao; Zhanguo Cao; Xinsheng Xu; Xu Xinsheng; Daquan Liu; Liu Daquan; Xiangyang Xin; Xin Xiangyang; Mingfang Qin
Journal:  Obes Surg       Date:  2015-01       Impact factor: 4.129

8.  Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient--2013 update: cosponsored by American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery.

Authors:  Jeffrey I Mechanick; Adrienne Youdim; Daniel B Jones; W Timothy Garvey; Daniel L Hurley; M Molly McMahon; Leslie J Heinberg; Robert Kushner; Ted D Adams; Scott Shikora; John B Dixon; Stacy Brethauer
Journal:  Obesity (Silver Spring)       Date:  2013-03       Impact factor: 5.002

9.  Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient--2013 update: cosponsored by American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic & Bariatric Surgery.

Authors:  Jeffrey I Mechanick; Adrienne Youdim; Daniel B Jones; W Timothy Garvey; Daniel L Hurley; M Molly McMahon; Leslie J Heinberg; Robert Kushner; Ted D Adams; Scott Shikora; John B Dixon; Stacy Brethauer
Journal:  Endocr Pract       Date:  2013 Mar-Apr       Impact factor: 3.443

10.  Insulin resistance and beta cell function before and after sleeve gastrectomy in obese patients with impaired fasting glucose or type 2 diabetes.

Authors:  Hans Eickhoff; Ana Guimarães; Teresa M Louro; Raquel M Seiça; Francisco Castro E Sousa
Journal:  Surg Endosc       Date:  2014-07-04       Impact factor: 4.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.